Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Genmab reported positive Phase 2 data for epcoritamab in elderly patients with newly diagnosed DLBCL, presented at the EHA 2026 Congress. In the EPCORE DLBCL-3 monotherapy arm, 66 patients showed a 67% overall response rate and 58% complete response rate, with a median progression-free survival of 13.0 months. In the EPCORE NHL-2 combination arm (epcoritamab plus R-mini-CHOP), 28 patients achieved a 93% overall response rate and 86% complete response rate, with 76% progression-free and 82% overall survival at two years.
Key figures
- Drug Name
- epcoritamab
- Phase Of Trial
- Phase 2
- Epcore dlbcl 3 n
- 66
- Epcore dlbcl 3 cr
- 58%
- Epcore dlbcl 3 orr
- 67%
- Epcore nhl 2 arm8 n
- 28
- Epcore nhl 2 arm8 cr
- 86%
- Epcore nhl 2 arm8 orr
- 93%
- Epcore nhl 2 arm8 2yr os
- 82%
- Epcore dlbcl 3 median age
- 82.5
- Epcore dlbcl 3 median pfs
- 13.0 months
- Epcore nhl 2 arm8 2yr pfs
- 76%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.